Friday 5 October 2012
Thursday 4 October 2012
Allied Health Group - Qualitative Analysis
June 2013 - Target Price $0.05c
Feb 2014 - Target Price $0.12c
Oct 2014 - Target Price $0.22c
Allied Healthcare Group
Allied Medical
Coridon Pty Ltd
Celxcel
2012 Highlights
Submitted European CE mark application for marketing authorisation of CardioCel®.
Regenerative medicine franchise is seeking approval in numerous jurisdictions.
The ADAPT® platform technology has potential to make a significant impact on the global market for structural heart defect repair, estimated at over $3Bn* .
ADAPT® TEP platform technology to be used in pelvic floor reconstructions, hernia repairs, orthopaedics and as a biological scaffold to grow and deliver stem cells.
Collaborating with CSIRO to develop ADAPT® treated tissue matrices as scaffolds for the delivery of adult mesenchymal stem cells in models of heart failure.
CardioCel® continues to gain support of key cardiothoracic surgeons
Additional authorisations for CardioCel® are expected to be announced in the near future
CardioCel®’s use in CHD patients fills a high unmet clinical need
Coridon gears up for highly anticipated herpes vaccine trial
Pre-clinical study of new DNA vaccine showing 100% protection against herpes simplex virus 2
Major milestones due within the next six months
• US regulatory filing update for CardioCel®
• Follow up data for heart valve reconstructions
• Data in pelvic floor and hernia repair
• Initial animal data for HPV vaccine programs
• Initiation of DNA HSV vaccine Phase I study
• Initial revenues from CardioCel® (first product from the regenerative medicine franchise)
The company continues to see some good revenue streams through its medical product supplies business unit, with additional income also being anticipated for FY2013 when CardioCel receives CE marking to commence European sales, and additional TGA authorisations are also expected over the near term. It is quite acceptable when looking at some of the significant milestones being acheived, as well as anticipated news flow due over the short term, for one to believe that AHZ share holders may soon be getting spoilt this Christmas, and most certainly early in the new year.
In my personal view, Prof Frazer's highly anticipated DNA Vaccine Trial due to commence in the short term, will attract substantial amount of media attention for a number of reasons: Prof. Frazer is already one of Australia's most successful and highly respected scientists, Australian of the year in 2006 and this year he received the highest accolade in the 2012 Queen's Birthday honours in June when he was appointed a Companion of the Order of Australia. Governor-General Quentin Bryce
said Professor Frazer's vaccine had changed the world.
Prof. Frazer, who invented the world's first cancer vaccine is now showing the same confidence in the development of his pioneering DNA vaccine against herpes simplex virus 2 (HSV-2) with results from a pre-clinical efficacy study already showing it to be 100% effective. Of course there are no guarantees in life, however there is also no alternative drug currently available to the millions of HSV-2 sufferers around the world today. One only needs to read the many comments posted in this article
to appreciate that millions of people will be hoping and praying for a successful outcome to these clinical trials, soon to get underway - I wish Prof. Frazer and his great team of research scientists all the very best of luck. Here's a qualitative analysis for Allied Health Group (ASX:AHZ) which currently hold 44% interest in Prof. Frazer's company, Coridon Pty Ltd
Subscribe to:
Posts (Atom)